It Takes the Right Medications to Prevent a Million Heart Attacks and Strokes

References

• . Roger VL, Go AS, Lloyd-Jones DM,. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–e220
   PubMed Web of Science ®Google Scholar
• . Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens. 2010;12(12):927–934
   PubMed Web of Science ®Google Scholar
• . Multiple Risk Factor Intervention Trail Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trail. Circulation. 1990;82(5):1616–1628
   PubMed Web of Science ®Google Scholar
• . Leren P, Helgeland A. Oslo Hypertension Study. Drugs. 1986;31(1):41–45
   PubMedGoogle Scholar
• . DiNicolantonio JJ. Hydrochlorothiazide: is it a wise choice? Expert Opin Pharmacother. 2012;13(6):807–814
   PubMed Web of Science ®Google Scholar
• . DiNicolantonio JJ, O'Keefe JH, Lavie CJ. Chlorthalidone versus hydrochlorothiazide. Ann Intern Med. 2013;158(12):920–921
   PubMedGoogle Scholar
• . Al Badarin FJ, Lavie CJ, O'Keefe JH. The last nail in hydrochlorothiazide's coffin? Ochsner J. 2012;12(1):4–6
   PubMedGoogle Scholar
• . Al Badarin FJ, Abuannadi MA, Lavie CJ, O'Keefe JH. Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. Am J Cardiol. 2011;107(8):1178–1184
   PubMed Web of Science ®Google Scholar
• . Carlberb B, Samuelsson O, Lindholm LH,. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364(9446):1684–1689
   PubMed Web of Science ®Google Scholar
• . Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545–1553
   PubMed Web of Science ®Google Scholar
• . Aurnes I, Osnes JB, Tvete IF,. Does atenolol differ from other β-adrenergic blockers? BMC Clin Pharmacol. 2007;7:4
   PubMedGoogle Scholar
• . Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J. 1992;204(6824):405–412
   Google Scholar
• . Wilhelmsen L, Berglund G, Elmfeldt D,. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5(5):561–572
   PubMed Web of Science ®Google Scholar
• . Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G, on behalf of the Advisory Committee. Primary prevention with metoprolol in patients with hypertension: mortality results from the MAPHY Study. JAMA. 1988;259(13):1976–1982
   PubMed Web of Science ®Google Scholar
• . Wikstrand J, Warnold I, Tuomilehto J,. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension. 1991;17(4):579–588
   PubMed Web of Science ®Google Scholar
• . Brener SJ, Cox JL, Pfisterer ME, Armstrong PW, Califf RM, Topol EJ, GUSTO Investigators. The potential for unexpected hazard of intravenous beta-blockade for acute myocardial infarction: results from the GUSTO trial. J Am Coll Cardiol. 1995;( suppl 5A):901–903
   Google Scholar
• . Lopressor Intervention Trial Research Group. Multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J. 1987;8(10):1056–1064
   PubMed Web of Science ®Google Scholar
• . DiNicolantonio JJ, Hackam DG. Carvedilol: a third-generation β-blocker should be a first-choice β-blocker. Expert Rev Cardiovasc Ther. 2012;10(1):13–25
   PubMedGoogle Scholar
• . DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol. 2013;111(5):756–759
   Web of Science ®Google Scholar
• . Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114(8):838–854
   PubMed Web of Science ®Google Scholar
• . van Vark LC, Bertrand M, Akkerhuis KM,. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–2097
   PubMed Web of Science ®Google Scholar
• . Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med. 2013;18(2):44–47
   PubMedGoogle Scholar
• . Lithell H, Hansson L, Skoog I,. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–886
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Teo K, Anderson C,. TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372(9644):1174–1183
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Diener HC, Sacco RL,. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225–1237
   PubMed Web of Science ®Google Scholar
• . McMurray JJ, Holman RR, Haffner SM,. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–1490
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Healey JS, Pogue J,. ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364(10):928–938
   PubMed Web of Science ®Google Scholar
• . Imai E, Chan S, Ymasaki T, et al, for the ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with over nephropathy: a multicenter, randomized, placebo-controlled study. Diabetologia. 2011;54(12):2978–2986
   PubMed Web of Science ®Google Scholar
• . Haller H, Ito S, Izzo J, et al, for the ROADMAP Trial investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–917
   PubMed Web of Science ®Google Scholar
• . Disertori M, Latini R, Barlera S,, GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606–1617
   PubMed Web of Science ®Google Scholar
• . Goette A, Schön N, Kirchhof P,. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. Circ Arrhythm Electrophysiol. 2012;5(1):43–51
   PubMed Web of Science ®Google Scholar
• . Yamashita T, Inoue H, Okumura K,. Randomized trial of angiotensin II-receptor blocker versus dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace. 2011;13(4):473–479
   PubMed Web of Science ®Google Scholar
• . Mauer M, Zinman B, Gardiner R,. Renal and retinal effects of enalapril and losartan in Type 1 diabetes. N Engl J Med. 2009;361(1):40–51
   PubMed Web of Science ®Google Scholar